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KAJIAN FITOKIMIA, FARMAKOLOGI DAN FARMAKOKINETIK LIGNAN  
PHYLLANTHUS NIRURI LINN. SEBAGAI AGEN ANTIHIPERURISEMIK BERPOTENSI  
 
ABSTRAK 
Ekstrak metanol dari daun Phyllanthus niruri L. menunjukkan aktiviti antihiperurisemik oral 
yang bergantungan dos di dalam tikus hiperurisemia yang diaruh dengan kalium oksonat 
dan asid urik. Fraksinasi ekstrak tersebut melalui kromatografi resin memberi fraksi kurang 
polar yang menunjukkan penurunan tertinggi dalam asid urik plasma. Penulenan 
seterusnya fraksi itu berdasarkan aktiviti antihiperurisemik menghasilkan empat lignan, 
filantin, hipofilantin, filtetralin dan nirantin. Struktur kimia sebatian-sebatian ini dielusidasi 
dan dikenalpasti melalui perbandingan takat lebur, spektra resonans magnetik nukleus, 
ultraungu, inframerah dan jisim mereka dengan nilai yang dilaporkan sebelumnya. Filantin 
menunjukkan kesan antihiperurisemik yang tertinggi bila dibanding dengan lignan yang 
lain. Pada 20 mg/kg, filantin menurunkan asid urik plasma ke tahap yang serupa dengan 
10 mg/kg benzbromaron dan allopurinol. Akan tetapi, filantin tidak berupaya untuk 
menurunkan secara signifikan asid urik plasma ke tahap lebih rendah daripada tahap tikus 
normourisemik walaupun pada dos tertinggi, 20mg/kg. 
  
Mekanisme bagi aktiviti antihiperurisemik P. niruri dan lignannya telah dikaji menggunakan 
esei enzim xantina oksidase dan kajian urikosurik. Ekstrak metanol P. niruri menunjukkan 
aktiviti perencatan xantina oksidase in vitro dan in vivo yang sederhana dengan masing-
masing IC50 sebanyak 39.39 μg/ml dan ED50 sebanyak 157.91 mg/kg. Akan tetapi, lignan 
tidak menunjukkan perencatan xantina oksidase in vitro dan menunjukkan aktiviti 
perencatan in vivo yang agak lemah pada 10 mg/kg. Sebaliknya, rawatan oral ekstrak 
metanol P. niruri (100 – 1000 mg/kg) menunjukkan aktiviti urikosurik dengan peningkatan 
sebanyak 1.10 hingga 7.14 ganda dalam ekskresi asid urik urin berbanding tikus 
 xxvi
hiperurisemik yang tidak menerima sebarang rawatan. Lignan, filantin, hipofilantin dan 
filtetralin pada 10 mg/kg turut menunjukkan ekskresi dan klearans asid urik lebih tinggi 
sehingga 2.51 dan 11.0 ganda, masing-masing lebih tinggi berbanding tikus hiperurisemik 
kawalan. Filantin menunjukkan potensi yang serupa dengan benzbromaron dan 
probenesid pada dos 10 mg/kg dan peningkatan dalam ekskresi serta klearans asid urik 
urin bergantung pada dos. Berdasarkan penemuan kajian ini, kesan antihiperurisemik 
ekstrak metanol P. niruri mungkin disebabkan terutamanya oleh kesan urikosurik dan 
sebahagian kecil melalui perencatan xantina oksidase, manakala kesan antihiperurisemik 
lignan diakibatkan oleh kesan urikosuriknya. Pemberian bersama pirazinamida dan 
benzbromaron atau filantin kepada tikus hiperurisemik menunjukkan penekanan signifikan 
dalam aktiviti urikosurik mereka tidak seperti tikus yang diberi pirazinamida bersama 
probenesid. Filantin menunjukkan aktiviti urikosurik menyerupai benzbromaron, mungkin 
melalui perencatan penyerapan semula pada tapak post-perembesan tubul berlingkar 
proksimal.  
 
Kaedah analisis baru yang mudah dan sensitif menggunakan kromatografi cecair prestasi 
tinggi dengan pengesanan pendarfluor telah dibangunkan untuk penentuan empat lignan 
yang telah dipencilkan. Kaedah ini mempunyai had pengesanan untuk filantin, hipofilantin, 
filtetralin dan nirantin sebanyak 80, 8, 80 dan 40 kali, masing-masing lebih sensitif 
berbanding nilai yang diperolehi dengan kaedah pengesanan ultraungu. Kaedah tersebut 
telah berjaya diaplikasi bagi kuantifikasi lignan dalam sampel pokok P. niruri serta dalam 
kajian farmakokinetik dan biokeperolehan lignan dalam tikus. Kandungan lignan tertinggi 
didapati pada daun, diikuti buah, dahan dan batang manakala bahagian akar mempunyai 
kandungan lignan paling rendah. Selepas pemberian intravena kepada tikus, lignan 
dikeluarkan secara perlahan dari badan dengan nilai klearans min yang kecil serta nilai 
separuh hayat min antara 3.35 hingga 4.40 jam. Kepekatan plasma puncak berikutan 
 xxvii
pemberian oral dicapai selepas 1 jam. Akan tetapi, penyerapan lignan tersebut tidak 
lengkap dengan nilai kiraan bagi biokeperolehan oral mutlak sebanyak 0.62, 1.52, 4.01 dan 
2.66 % masing-masing untuk filantin, hipofilantin, filtetralin dan nirantin.  
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PHYTOCHEMICAL, PHARMACOLOGICAL AND PHARMACOKINETIC STUDIES OF 
PHYLLANTHUS NIRURI LINN. LIGNANS AS POTENTIAL ANTIHYPERURICEMIC AGENTS 
 
ABSTRACT 
The methanol extract from the leaves of Phyllanthus niruri L. showed dose-dependent oral 
antihyperuricemic activity in potassium oxonate- and uric acid-induced hyperuricemic rats. 
Fractionation of the extract by resin chromatography gave a less polar fraction which 
exhibited the highest reduction of plasma uric acid.  Further antihyperuricemic-guided 
purification of the fraction afforded four lignans, phyllanthin, hypophyllanthin, phyltetralin 
and niranthin. Their structures were elucidated and confirmed by comparison of their 
physico-chemical properties, nuclear magnetic resonance, ultraviolet, infrared and mass 
spectra with those reported previously. Phyllanthin showed the highest dose-dependent 
antihyperuricemic effect when compared with that of the other lignans. At 20 mg/kg, 
phyllanthin decreased the plasma uric acid to the same extent as 10 mg/kg of 
benzbromarone and allopurinol. However, phyllanthin was not able to significantly reduce 
the plasma uric acid level below that of normouricemic rats even at the highest dose        
of 20 mg/kg. 
 
The mechanisms of antihyperuricemic activity of P. niruri and its lignan constituents were 
investigated using the xanthine oxidase enzyme assay and uricosuric studies. P. niruri 
methanol extract exhibited moderate in vitro and in vivo xanthine oxidase inhibitory activity 
with an IC50 of 39.39 μg/ml and an ED50 of 157.91 mg/kg, respectively.  However, the 
lignans did not display xanthine oxidase inhibition in vitro and showed a relatively weak    
in vivo inhibitory activity at 10 mg/kg. On the other hand, oral treatment with P. niruri 
methanol extracts (100 - 1000 mg/kg) showed uricosuric activity of 1.10 to 7.14 folds 
increase in urinary uric acid excretion when compared to the non-treated hyperuricemic 
rats. Likewise, the lignans, phyllanthin, hypophyllanthin and phyltetralin at 10 mg/kg 
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exhibited up to 2.51 and 11.0 fold higher in urinary uric acid excretion and clearance, 
respectively compared to the hyperuricemic control rats. Phyllanthin at 10 mg/kg increased 
the urinary uric acid excretion and clearance in a dose-dependent manner and exhibited 
similar potency with those of benzbromarone and probenecid. Based on the findings of the 
present study, it seems very likely that the antihyperuricemic effect of  P. niruri methanol 
extract may be attributable mainly to its uricosuric action and partly through xanthine 
oxidase inhibition, while the antihyperuricemic effect of the lignans was attributable to their 
uricosuric action. The co-administration of pyrazinamide with benzbromarone or 
phyllanthin to the hyperuricemic rats exhibited a significant depression of their uricosuric 
activity unlike those rats given pyrazinamide and probenecid. Phyllanthin showed 
uricosuric activity resembling that of benzbromarone, probably by the inhibition of 
reabsorption at the post-secretory site of the proximal convulated tubule.  
 
A new, simple and sensitive analytical method using HPLC with fluorescence detection 
was developed for the simultaneous determination of the four isolated lignans. The method 
recorded limits of detection for phyllanthin, hypophyllanthin, phyltetralin and niranthin of 
80, 8, 80 and 40 times, respectively more sensitive than those derived from the HPLC-UV 
detection method. The method was successfully applied for quantification of the lignans in 
P. niruri plant samples and pharmacokinetic and bioavailability studies of the lignans in 
rats. The highest amount of lignans was found in the leaves followed by the fruits, 
branches and stem whilst the roots have the least amount of lignans. Following 
intravenous administration to the rats, the lignans were eliminated slowly from the body 
with a small mean clearance value and a mean half-life of 3.35 to 4.40 hr. Their peak 
plasma concentration upon oral administration was achieved after 1 hr. However, their 
absorption was incomplete with a calculated absolute oral bioavailability of 0.62, 1.52, 4.01 
and 2.66 % for phyllanthin, hypophyllanthin, phyltetralin and niranthin, respectively. 
 1
CHAPTER ONE 
INTRODUCTION  
 
1.1      Hyperuricemia: A global scenario and its management 
Hyperuricemia or high level of blood uric acid is a common biochemical abnormality 
encountered in clinical practice. About 10 % of adults are documented to have 
hyperuricemia at least once in their lifetime (Dincer et al., 2002). The prevalence of 
hyperuricemia in the general population has been reported to be from 5 to 30 %, 
although it is higher in some ethnic groups (Vazquez-Mellado et al., 2004). For 
instance, Klemp et al. (1997) reported that hyperuricemia was more commonly found in 
Maori men (27.1 %) than in European men (9.4 %) while Chou and Lai (1998) reported 
that the prevalence of hyperuricemia was 41.4 % among Taiwan aborigines. 
Meanwhile, Li et al. (1997) found that the prevalence of hyperuricemia were higher in 
urban than rural population of Beijing. Hyperuricemia seems to be more prevalent 
worldwide, probably due to improvements in standard of living, increasing longevity and 
the usage of certain drugs such as salicylate and pyrazinamide. This has resulted in 
significant morbidity and increase in costs of the health care system (Vazquez-Mellado 
et al., 2004; Kim et al., 2003; Klemp et al., 1997).  
 
Hyperuricemia is often associated with a number of human diseases (Ruilope and 
Garcia-Puig, 2001). Classically, hyperuricemia is a major risk factor for gout, 
urolithiasis and uric acid nephropathy. In addition, it has also been linked with other 
diseases such as diabetes mellitus, preeclampsia, hypertension, vascular diseases and 
stroke or clinical symptoms such as lipid abnormalities, insulin resistance and obesity 
(Kim et al., 2003; Dincer et al., 2002; Ghei et al., 2002; Li et al., 1997; Campion et al., 
1987). These complications develop depending on both the level and duration of 
hyperuricemia.  
 2
Primary intervention in patients with symptomatic hyperuricemia or its associated gout 
include patient education, lifestyle changes and pharmacological therapy. Lifestyle 
modifications such as weight reduction, decreased alcohol consumption and dietary 
purine intake may help to decrease blood uric acid. However, many patients will still 
need medication to control their hyperuricemia (Kong et al., 2004; Wright and Pinto, 
2003; Liote, 2003; Wood, 1999). Despite a long history of hyperuricemia and gout, 
there are only a limited number of drugs currently used in clinical practice and they 
belong to two classes, the xanthine oxidase (XO) inhibitors and the uricosuric agents. 
An example of clinically used XO inhibitor is allopurinol, while uricosuric agents include 
probenecid and benzbromarone.  
 
XO inhibitors reduce the blood uric acid level by inhibition of XO enzyme that is 
responsible for the formation of uric acid from purines.  Consequence to the inhibition, 
the blood and urinary concentrations of uric acid are reduced and there is a 
simultaneous increase in the excretion of the more soluble uric acid precursors, 
xanthine and hypoxanthine. Patients who are categorized as overproducers of uric acid 
or those with renal insufficiency are best treated with XO inhibitors (Wright and Pinto, 
2003; Wood, 1999). 
 
Allopurinol was developed in 1956 for use as an adjuvant in chemotherapy, however, it 
was found to possess the ability to lower serum uric acid level (Khoo and Leow, 2000). 
Allopurinol (1) (4-hydroxypyrazolo [3,4-d] pyrimidine) is a potent inhibitor and substrate 
for XO. It is the only clinically available drug belonging to the XO inhibitor group that is 
most widely prescribed for the management of hyperuricemia and gout (Dincer et al., 
2002; Khoo and Leow, 2000). It has been used for the therapy of both primary 
hyperuricemia and gout or secondary hyperuricemia that is due to haematological 
disorders or antineoplastic therapy. A response to allopurinol is seen about two days 
after initiation of therapy and is maximal after about seven to ten days (Wood, 1999).  
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Allopurinol itself is metabolized by the XO enzyme, to its active metabolite oxypurinol 
(2). Although the half-life of allopurinol is 1 to 3 hours, its metabolite has a longer half-
life ranging from 18 to 33 hours, thus prolonging the therapeutic effectiveness of 
allopurinol administered as a single dose (Spector, 1977). Common adverse effects 
associated with allopurinol administration include a variety of skin rashes, 
hypersensitivity, gastrointestinal upset, hepatotoxicity, hepatitis and fever.  
Approximately 2 to 10 % of patients, especially the elderly with renal impairment, have 
developed a pruritic erythematous rash, which prevented further administration of 
allopurinol (Fam, 2001; Khoo and Leow, 2000). A more severe and life threatening 
hypersensitivity syndrome in which patients develop toxic epidermal necrolysis, fever, 
hepatitis, eosinophilia and deterioration of renal function has also been reported in 
approximately 0.4 % of patients (Zhu et al., 2004; Dincer et al., 2002; Kong et al., 2002; 
Fam, 2001; Khoo and Leow, 2000; Wood, 1999; Osada et al., 1993). The use of 
allopurinol has also led to the appearance of allopurinol allergic-patients throughout the 
world (Fam, 2001).  
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Recently, febuxostat (3) [2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic 
acid], a selective inhibitor of XO was developed in Japan. Febuxostat may become an 
alternative effective drug to allopurinol for use in the treatment of hyperuricemia and 
gout (Takano et al., 2005; Komoriya et al., 1993; Osada et al., 1993). Clinical trials on 
the efficacy and tolerability of febuxostat in normal subjects and patients with 
hyperuricemia or gout, have found that the drug significantly reduced the serum uric 
acid level in a dose-dependent manner at a lower dose than allopurinol (Bruce, 2006; 
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Becker et al., 2005a; Becker et al., 2005b). It was generally well tolerated; the most 
common adverse effects were liver function abnormalities, diarrhea, headache, 
nausea, vomiting, abdominal pain, arthralgias and musculoskeletal symptoms (Bruce, 
2006; Pohar and Murphy, 2006).  
In contrast to the XO inhibitors, drugs belonging to the uricosuric group reduce the 
blood uric acid level by increasing its excretion. This agent competes with uric acid for 
the transport sites at the proximal tubules. Patients who are categorized as 
underexcretors of uric acid are the best candidates for uricosuric therapy (Perez-Ruiz 
et al., 1998).  Uricosuric drugs may also be used in patients who are intolerant of 
allopurinol but they are relatively ineffective in patients with poor renal function. The 
greatest potential risk of therapy with uricosuric drugs is the deposition of uric acid in 
the collecting tubules (Wright and Pinto, 2003; Wood, 1999).  
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Probenecid (4) [p-(dipropylsulfamoyl) benzoic acid] was initially developed in search for 
a drug to sustain blood level of penicillin by interfering with its renal excretion. In 
addition, it also inhibits the reabsorption of uric acid at the proximal tubule, thereby 
causing an increase in uric acid excretion. However, probenecid has a so-called 
“paradoxical effect”, whereby at therapeutic doses, it increases uric acid excretion while 
at much lower doses it decreases uric acid excretion (Dan and Koga, 1990; Frankfurt 
and Weinman, 1977).   
 
Another uricosuric agent, benzbromarone (5) [3-(3,5-dibromo-4-hydroxybenzoyl)-2 
ethylbenzofuran] also causes an increase in excretion of uric acid. However, the 
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paradoxical effect observed with probenecid is absent with benzbromarone. XO 
inhibition by benzbromarone was shown in some animal studies; however it does not 
inhibit XO in humans (Heel et al., 1977). Benzbromarone is conjugated in the liver and 
excreted to the bile. Although it is effective in patients with renal insufficiency, it 
possesses a risk of severe hepatotoxicity (Dincer et al., 2002; Fam, 2001; Perez-Ruiz 
et al., 1998).  
 
Besides the two classes of drugs, other pharmacological agents may also be used for 
the treatment of hyperuricemia and gout. Losartan and fenofibrate, in addition to their 
principal pharmacological activities, have blood uric acid lowering effect. Both of them 
diminish uric acid reabsorption at the proximal tubule and increase its excretion 
(Vazquez-Mellado et al., 2004). 
 
Generally in most patients, allopurinol or any of the uricosuric drugs will allow the 
achievement and maintenance of normouricemia. However in patients with co-
morbidities such as renal insufficiency, renal calculi, transplantation or allopurinol 
allergy, treatment options are narrow and could complicate the management of 
symptomatic hyperuricemia or gout (Kim et al., 2003). Thus, a continuous development 
of novel antihyperuricemic drugs would be of great interest. 
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1.2 Literature review 
 
1.2.1 Biochemistry and physiology of uric acid  
Uric acid (2,6,8-trioxypurine) is a weak organic acid, due to the ionisable hydrogen at 
position 3 with an ionization constant of 5.75. This physicochemical property is an 
important determinant of the concentration and form of uric acid in the circulation or 
tissues. At pH 7.4 such as in blood or synovial fluids, about 98 % of uric acid is ionized 
as monosodium urate whereas at lower pH such in the urine, it exists mostly in free 
form (Ruilope and Garcia-puig, 2001).  
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1.2.1.1    Biosynthesis and regulation of uric acid formation 
The pool of uric acid in human is a balance between endogenous or exogenous 
sources of uric acid and degradation or elimination of uric acid. The exogenous 
sources for uric acid are the purine and purine precursors in the diets. Two 
endogenous sources contributing to the miscible pool of uric acid, firstly is the tissue 
catabolism via the breakdown of nucleic acids and nucleotides, and secondly is the de 
novo purine biosynthetic pathway (Newcombe, 1975).   
 
The pathways for biosynthesis of purines and formation of uric acid are shown in 
Figure 1.1.  5-Phosphoribosyl-1-pyrophosphate (PRPP) is the starting compound for 
purine biosynthesis, which can also react with the preformed purine bases to form 
purine ribonucleotides directly by the so-called “salvage pathways” (Newcombe, 1975). 
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The first purine formed is inosinic acid that will be converted to free purine bases by 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Part of the bases is 
reutilized through the salvage reaction with PPRP, and the remainders is degraded to 
free bases xanthine and hypoxanthine. Xanthine oxidoreductase (XOR) enzymes, 
convert both of these bases to uric acid (Seegmiller, 1976). They are known as the 
rate-limiting enzymes in purine catabolism. 
 
5-Phosphoribosyl-1-pyrophosphate (PRPP)  +  Glutamine
5-Phosphoribosyl-1-amine
Formyl glycinamide ribonucleotide
Inosinic Acid
Inosine
Hypoxanthine
Xanthine
Uric acid (UA)
Guanylic acid
Guanine
Adenosine
Adenylic acid
Adenine
Guanosine
Glycine
Formate
   HGPRT
PR
PP
PRPP
Feedback inhibition Feedback inhibition
 
Figure 1.1 Pathways for biosynthesis of purines and the formation of uric acid 
(Seegmiller, 1976).  
 
Xanthine oxidase (XO; EC 1.1.3.22) and xanthine dehydrogenase (XD; EC 1.1.1.204) 
are both members of the molybdenum hydroxylase flavoprotein family and often 
referred to as XOR (Pritsos, 2000). Structurally, XOR is a homodimer of 150-kDa 
subunits, with a N-terminal domain containing two iron-sulphur centres (Fe/S I and 
Fe/S II), a middle domain containing flavin adenine dinucleotide (FAD) site and a C-
terminal domain containing a molybdenum cofactor and substrate binding site. 
Conversion of XD into XO form can be achieved by a variety of treatment, such as 
storage at -20 °C, adding proteolytic enzymes, organic solvents or thiol reagents  and 
preincubation under anaerobic conditions (Delle-Corte and Stripe, 1972).  
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In mammals, the liver and intestine have the highest XOR activity (Pritsos, 2000; 
Krenitsky et al., 1986). The primary structure, catalytic properties and cofactor 
requirements of XOR are highly conserved with a 90 % homology among rat, mouse 
and human XOR enzymes (Pritsos, 2000).  The XOR enzymes catalyze the oxidation 
of hypoxanthine to xanthine and xanthine to uric acid.  However, their mechanisms of 
action are different in that the XD reduces NAD+ (nicotinamide adenine dinucleotide) by 
a direct two-electron reduction whereas XO reduces molecular oxygen by a single 
electron. During the process, the substrates hypoxanthine and xanthine bind to the 
molybdenum site, and the electron acceptors NAD+ and O2 interact with the FAD 
cofactor (Pritsos, 2000; Fujimoto et al., 2000, Mondal et al., 2000).  
 
1.2.1.2    Degradation of uric acid 
Uric acid is formed mainly in the liver and only a small percentage (less than 5%) is 
bound to plasma proteins. Significant differences exist among the animals in the 
degradation of uric acid, whereby the lower forms of animal life possess a full 
complement of enzymes necessary for degrading uric acid completely into allantoin (7), 
allantoic acid (8) and urea (9) as shown in Figure 1.2 (Hitchings, 1978).   
 
CH(NHCONH2)2
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O
O
H2NCONH
2H2NCONH2
allantoicase
uricase allantoinase
6 uric acid 7 allantoin
8 allantoic acid 
9 urea  
 
Figure 1.2       Enzymatic degradation of uric acid (Hitchings, 1978). 
 
Most mammals possess the enzyme, uricase that catalyzes the degradation of uric 
acid to a more soluble allantoin (Ghei et al., 2002; Ruilope and Garcia-Puig, 2001). 
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Only in man and great apes, uric acid remains as the end product of purine catabolism. 
Thus,  humans have relatively higher level of blood uric acid (Wu et al., 1992). 
 
1.2.1.3    Uric acid disposal 
The kidney and gut are the main routes for the disposal of uric acid.  Approximately   
70 % of the uric acid is eliminated via the kidney while the remaining 30 % via the 
billiary and gastrointestinal system, where it undergoes degradation to allantoin by 
colonic bacteria. In individuals with renal insufficiency, the gastrointestinal track may be 
the major route of uric acid disposal. Mammals can be divided into two groups based 
on the net bidirectional transport of uric acid in the renal.  Net reabsorption occurs in 
humans and other species such as cebus monkey, rats, mice and dogs whereas net 
secretion occurs in pigs and rabbits (Yamada et al., 1999a; Roch-Ramel and Peters, 
1978).  
 
The renal mechanisms involved in the handling of uric acid are complex. Proximal 
convulated tubules are the main sites of transtubular uric acid transport in humans as 
well as most animals. Renal handling of uric acid is considered to involve a four 
compartment model. Firstly, blood uric acid undergoes glomerular filtration followed by 
the second step, pre-secretory reabsorption at the first segment (S1) of the proximal 
tubule. The capacity of reabsorption at initial proximal tubule is large, where more than 
95 % of the filtered uric acid will be reabsorbed, even in the presence of hyperuricemia 
(Liote 2003, Roch-Ramel and Peters, 1978). The third step involves uric acid secretion 
at the second segment (S2) followed by the fourth step,  post-secretory reabsorption at 
the last segment (S3) of the proximal tubule (Itagaki et al., 2005; Ghei et al., 2002; 
Yamada et al., 1999b; Steele, 1999).  Based on the model, it has been reported that 
benzbromarone inhibits post-secretory reabsorption, while probenecid mainly inhibits 
post-secretory and partly inhibits pre-secretory reabsorption (Yamada et al., 1999b; 
Dan et al., 1990; Levinson and Sorenson, 1980; Heel et al., 1977). 
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Following glomerulus filtration, uric acid enters the proximal tubule in its anionic form 
and due to its hydrophilic nature it hardly permeates the proximal tubular cells. At brush 
border membrane (BBM) of the proximal tubular cells, uric acid is transported by two 
distinct mechanisms, an anion exchanger and a voltage-dependent mechanism. Anion 
exchangers allow bidirectional transport and have been suggested to play a major role 
in uric acid reabsorption (Itagaki et al., 2005; Enomoto et al., 2002; Roch-Ramel and 
Guisan, 1999; Roch-Ramel et al., 1994; Guggino et al., 1983). The anion exchangers 
accept multiple monovalent organic anion, aliphatic or aromatic as well as chloride, 
bicarbonate and hydroxyl ions (Guggino et al., 1983; Kahn et al., 1983). Some of the 
endogenous compounds and drugs that may interfere with tubular transport of uric acid 
are listed in Table 1.1 (Roch-Ramel and Guisan, 1999). 
 
 
Table 1.1: Substances that alter the renal tubular handling of uric acid (Roch-Ramel 
and Guisan, 1999) 
 
Substances that decrease uric acid 
excretion 
 
Substances that increase uric acid 
excretion 
Lactate 
Acetoacetate 
β-Hydoxybutyrate 
Nicotinate 
Pyrazinamide/pyrazinoate 
Probenecid 
Sulfinpyrazone 
Benzbromarone 
Losartan (antihypertensive drug) 
Tienilic acid (diuretic) 
 
 
Potential-sensitive transport system plays an important role in the efflux of organic 
anions including uric acid across BBM in rats, because the intracellular compartment 
has a more negative electrical potential than that of the luminal fluid in the proximal 
tubules (Itagaki et al., 2005; Roch-Ramel et al., 1994). Extracellular fluid volume (ECF) 
is another factor that influences the excretion of uric acid.  Expansion of ECF will 
reduce the tubular reabsorption of uric acid. However the changes in the urine flow or 
pH have no effect in the excretion of uric acid (Steele, 1999). 
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1.2.2   Hyperuricemia 
Hyperuricemia is defined as blood uric acid level of more than 7 mg/dl (420 μmol/L) in 
men or more than 6 mg/dl (360 μmol/L) in women (Vazquez-Mellado et al., 2004; Kim 
et al., 2003; Ruilope and Garcia-Puig, 2001). Ruilope and Garcia-Puig (2001) defined a 
blood uric acid level of more than 9 mg/dL as a severely hyperuricemic condition. 
Hyperuricemia results from overproduction or underexcretion of uric acid. About 80 to 
90 % of the patients with hyperuricemia or gout are underexcretors of uric acid 
(Vazquez-Mellado et al., 2004).  
 
Table 1.2: Classification of hyperuricemia 
 
1)   Increased formation of uric acid  
Inherited enzyme defects Hyperactivity of PRPP synthetase 
Decreased activity or deficiency of HGPRT 
Disease states leading to purine 
overproduction 
Myeloproliferative disorders 
Malignancies 
Hemolytic anaemia 
Increased catabolism or decreased 
synthesis of adenosine triphosphate 
Alcohol consumption 
Tissue hypoxia  
Excessive muscular exercise 
Associated with drugs or dietary habits Cytotoxic agents 
Fructose  
Excessive purine intake 
 
2)   Decreased renal clearance of uric acid  
Inherited defects of tubular function  - 
Disease states leading to reduced uric 
acid clearance 
 
Renal insufficiency 
Dehydration 
Acidosis (tissue hypoxia) 
Hyperparathyroidism 
Hypothyroidism 
Associated with drugs  Diuretics (thiazide and loop)   
Ethanol 
Pyrazinamide 
Salicylates  
Cyclosporin 
 
Genetic factors could be the major contributor to the high prevalence of hyperuricemia 
in some ethnic groups (Vazquez-Mellado et al., 2004). Other factors which may 
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influence the blood uric acid concentration are age, sex, body weight, body surface 
area, body mass and socioeconomic status of an individual (Garcia-Puig et al., 1986). 
Hyperuricemia can be classified as primary or secondary based on the underlying 
causative factors. Table 1.2 summarizes the pathophysiologic classification of 
hyperuricemic disorders and their respective underlying causes (Kim et al., 2003; 
Ruilope and Garcia-puig, 2001; Nakanishi et al., 1999; Li et al., 1997). 
 
 
1.2.2.1 Experimental hyperuricemia in rodents  
The presence of the enzyme uricase, is responsible for the lower plasma uric acid 
concentration observed in rodents. For example, the plasma uric acid concentration of 
normal rats ranges from 0.4 to 1.5 mg/dl  (20 to 90 μg/ml) (Roch-Ramel and Peters, 
1978).  Thus, to make the rodents more similar to man for studying hyperuricemia, the 
activity of uricase has to be reduced or eliminated. Experimentally, uricase activity in 
the liver can be suppressed either by uricase inhibitors, destroying a large part of the 
liver or by reducing the blood flow through the liver. By far, the most common method 
employed is by using uricase inhibitors such as salts of oxonic acid or analogs of 
xanthine and hypoxanthine such as 2,8-diazahypoxanthine, 2-azahypoxanthine,         
8-azaxanthine and 8-azahypoxanthine (Newburger et al., 1979; Roch-Ramel and 
Peters, 1978; Iwata et al., 1973). Recently, transgenic hyperuricemic mice have been 
developed by removal of the uricase gene (Wu et al., 1994; Bradely and Caskey, 
1984).  
 
Potassium oxonate  is commonly used for induction of hyperuricemia in experimental 
animals, given either as injections or added to the diet.  It has potent inhibitory effect on 
uricase enzyme but has comparatively insignificant effect on XO or on the transport of 
uric acid along the nephron (Mazzali et al., 2002; De Rougement et al., 1976; Iwata    
et al., 1972; Johnson et al., 1969; Fridovich, 1965).  Potassium oxonate given as a 
single injection or as an injection followed by intravenous infusion causes 
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hyperuricemia that peaks at 1.5 to 2 hours and lasts for at least 5 hours (Kang et al., 
2002; Yonetani and Iwaki, 1983; Roch-Ramel and Peters, 1978). However, potassium 
oxonate is apparently metabolized or excreted rapidly, thus frequent injections are 
required to sustain uricase inhibitory activity. When potassium oxonate was given in the 
diet, blood uric acid level peaked at two weeks in the rats, then gradually decreased 
over the following 4 weeks, which may reflect enhanced extrarenal excretion and 
depressed production of uric acid (Kang et al., 2002).  
 
Most studies on animal hyperuricemia have employed simultaneous feeding of 
potassium oxonate (2 - 5 %) with other agents such as uric acid (1 - 3 %) or fructose to 
produce a higher and sustained level of plasma uric acid (Nakagawa et al., 2003; Habu 
et al., 2003; Mazzali et al., 2001; Newburger et al., 1979; Roch-Ramel and Peters, 
1978; Starvic et al., 1976; Johnson et al., 1969). Fructose intake results in excess 
production of uric acid due to an increased degradation of nucleotides (Fields et al., 
1996; Fox and Kelley, 1972). However, addition of uric acid or fructose alone to the 
normal diet, produced no appreciable effect on plasma uric acid (Johnson et al., 1969). 
 
In oxonate- and uric acid-induced hyperuricemic animals, marked uricosuria was 
observed and the uric acid concentration in the renal tissue was considerably high 
causing intrarenal crystal deposition, interstitial nephritis and obstructive renal disease, 
as well as other impaired renal functions such as sodium, calcium and phosphate 
reabsorption and glomerular filtration (Habu et al., 2003; Kang et al., 2002; Mazzali     
et al., 2002; Brown et al., 1980; Roch-Ramel and Peters, 1978).  
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1.2.3     Role of medicinal plants and natural products in hyperuricemia 
Traditional medicines are used in primary health care by about 75 to 80 % of the world 
population, especially in developing countries. The use of herbal medicine is also 
popular in some developed countries such as Germany, France and United States of 
America. The herbs and herbal extract sales in European Union and United States of 
America are estimated to be over US $ 20 billion and $ 8 billion annually, respectively, 
while the worldwide herbal medicine market is estimated to be $ 30 - 60 billion 
(Kamboj, 2000). Hitherto, medicinal plants have been the source for a number of 
clinically important drugs such as morphine, atropine and digoxin and are excellent 
sources of lead compounds in the search for new drugs.   
 
Diverse medicinal plants and natural products have been investigated as inhibitors of 
XO enzyme.  Natural XO inhibitors from in vitro studies were reported from a variety of 
plants used as traditional herbal medicines such as Coccinia grandis and Vitex 
negundo in India (Umamaheswari et al., 2007), Chrysanthemum sinense and Tetracera 
scandens in Vietnam (Nguyen et al., 2004), Cleodendrum floribundum, Eremophila 
maculata and Stemodia grossa in Australia (Sweeney et al., 2001), Cinnamomum 
cassia, Chrysanthemum indicum and Lycopus europaeus in China (Kong et al., 
2000a), Larix laricina in North America (Owen and Johns, 1999), Hyptis obtusiflora and 
Hyptis lantanaefolia in Panama (Gonzalez et al., 1995) and Hexachlamys edulis and 
Eugenia punicifolia in Paraguay (Theduloz et al., 1988).  In general, the methanol 
extracts were found to be more active than the methanol-water or water extracts 
(Nguyen et al., 2004; Kong et al., 2000a). Chemical constituents from the flavonoids, 
polyphenols, tannins, xanthones, coumarins, β-carbolines and hydroxychalcones 
groups have been found to be potent inhibitors of XO (Owen and Johns, 1999; 
Gonzalez et al., 1995; Hatano et al., 1990; Hayashi et al., 1988; Noro et al., 1983).  
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Despite these findings, only a few of the natural products were evaluated for their 
antihyperuricemic activity in vivo using hyperuricemic animal models. Kong et al. 
(2004) reported that the extracts of a herbal mixture, Ermiao wan, containing 
phellodendri cortex and atractylodis rhizome, showed potent hypouricemic effect both 
in hyperuricemic and normal mice, whereas Zhu et al. (2004), showed that orally 
administered Biota orientalis extract reduced serum uric acid level of hyperuricemic 
mice. Similarly, Zhao et al. (2006) found that cassia oil extracted from Cinnamomum 
cassia reduced serum and hepatic uric acid level of hyperuricemic mice in a time- and 
dose-dependent manner partly by the inhibition of XO.  
 
Scopoletin (10) isolated from Erycibe obtusifolia (Ding et al., 2005), aesculin (11) from 
Fraxinus rhynchophylla (Kong et al., 2002), quercetin (12) and rutin (13) from Biota 
orientalis (Zhu et al., 2004) exhibited a potent antihyperuricemic effect after 
administration in hyperuricemic mice or rats.  The effect of quercetin  and rutin  was 
mediated by inhibition of XO activity whereas, the effect of scopoletin was by both 
inhibition of XO activity and uricosuric pathway. 
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The search for new antihyperuricemic agents from medicinal plants and natural 
products is ongoing. Presently, the largest underexplored rainforest for the discovery of 
new drugs lies in tropical and subtropical regions of the world (Nguyen et al., 2004). 
Malaysia being in this region is well known for its diverse nature and forest. Malaysians 
also use traditional and herbal remedies as an alternative choice for the prevention and 
treatment of diseases including gout and rheumatism. However, the validity of these 
claims has not been scientifically proven and therefore, is of interest to evaluate the 
antihyperuricemic effect of local Malaysian plants. 
 
 
1.2.4  Phyllanthus niruri L. 
 
1.2.4.1   Botanical aspects and geographical distributions 
Kingdom : Plantae 
Division : Magnoliophyta 
Class  : Magnoliopsida 
Order  : Euphorbiales 
Family  : Euphorbiaceae 
Genus  : Phyllanthus 
Species : niruri   
 
Figure 1.3 Phyllanthus niruri L.; (A) whole plant (B) aerial part (C) leaves.  
A
B 
C 
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Phyllanthus niruri L., known locally as “dukong anak”, is found in most tropical and 
subtropical regions, commonly in fields, grasslands and forests. It is a small herb that 
grows up to 60 cm in height and can easily be differentiated from shrub species such 
as P. pulcher or P. reticulatus. The plant is quite herbaceous unlike P. urinaria,            
P. simplex or P. maderaspantesis which are woody at base (Unader et al., 1995; 
Calixto et al., 1998; Ridley, 1967).  Its leaves are small and appear oblong with very 
short or absent petiole. The flowers are numerous, white to greenish in colour and 
minute, grouping at the axillary with a pedicel longer than P. urinaria. The fruit is a 
smooth surface and glabose capsule, in contrast to P. urinaria that has a echinate or 
warty capsule (Bee, 1964; Wiart, 2002).  
 
1.2.4.2    Chemical constituents of Phyllanthus niruri L. 
P. niruri has been the subject of much phytochemical studies since the mid 1960s. 
Different classes of organic compounds with various medical interest have been 
reported, the major being the lignans, tannins, polyphenols, alkaloids, flavonoids, 
terpenoids and steroids (Calixto et al., 1998). The following chemical constituents have 
been isolated from P. niruri.  
 
Lignans 
Lignans isolated from P. niruri mostly belongs to two groups, the 1,4-diarylbutane and 
1-aryltetralin though neolignans and lignans with other skeleton were also reported 
from this plant. The following lignans have been isolated from P. niruri: 
      
 
  1,4-diarylbutane skeleton    1-aryltetralin skeleton 
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 Diarylbutane lignans 
Phyllanthin (14) (Row and Srinivasalu, 1964), niranthin (15) (Anjaneyulu et al., 1973), 
seco-isolariciresinol trimethyl ether (16), hydroxyniranthin (17) (Satyanarayana et al., 
1988), nirphyllin (18) (Singh et al., 1989a), 2,3-desmethoxy seco-isolintetralin (19),     
2,3-desmethoxy seco-isolintetralin diacetate (20), linnanthin (21), demethylenedioxy-
niranthin (22) (Satyanarayana and Venkateswarlu, 1991).  
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14  phyllanthin     R1 = R2 = CH3 R3 = R4 = H   R5 = R6 = CH3 
15  niranthin     R1 + R2 = CH2 R3 = CH3  R4 = H  R5 = R6= CH3 
16  seco-isolariciresinol trimethyl ether R1 = R2 = CH3  R3 = R4 = R5 = H   R6 = CH3 
17  hydroxyniranthin    R1 + R2 = CH2 R3 = CH3 R4 = OH R5 = R6= CH3 
19  2,3-desmethoxyseco-isolintetralin R1 + R2 = CH2   R3 = R4 = R5 = R6 = H 
20  2,3-desmethoxyseco-isolintetralin diacetate R1 + R2 = CH2R3 = R4 = H R5 =R6 = COCH3 
21  linnanthin     R1 = R2 = R3 = CH3   R4 = H   R5 = R6 = CH3 
22  demethylenedioxyniranthin  R1 = R2 = H  R3 = CH3   R4 = H   R5 = R6 = CH3 
 
 
 Aryltetralin lignans 
Hypophyllanthin (23) (Row and Srinivasulu, 1964), nirtetralin (24), phyltetralin (25) 
(Anjaneyulu et al., 1973), lintetralin (26) (Ward et al., 1979), isolintetralin (27) (Huang et 
al., 1992), neonirtetralin (28) (Wei et al., 2002). 
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18  nirphyllin     23  hypophyllanthin 
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24  nirtetralin  R1+ R2 = CH2  R3 = OCH3  R4 = R5 = CH3 
25  phyltetralin R1 = R2 = CH3  R3 = H  R4 = R5 = CH3 
26  lintetralin  R1 = R2 = CH3  R3 = H  R4 + R5 = CH2 
27  isolintetralin R1 + R2 = CH2  R3 = H  R4 = R5 = CH3 
28  neonirtetralin R1+ R2 = CH2  R3 = OCH3  R4 = R5 = CH3 
 
 
 Other lignans 
Seco-4-hydroxylintetralin (29), dibenzylbutyrolactone (30) (Satyanarayana et al., 1988), 
hinokinin (31) (Huang et al., 1992). 
 
 Neolignan 
Phyllnirurin (32) (Singh et al., 1989a). 
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29  seco-4-hydroxylintetralin                            30  dibenzylbutyrolactone  
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31  hinokinin                  32  phylnirurin 
 
 
 
 
Coumarins, tannins and related polyphenols 
The following coumarins, tannins and polyphenols have been isolated from P. niruri: 
gallic acid (33), ellagic acid (34), brevifolin carboxylic acid (35), ethyl brevifolin 
carboxylate (36) (Shmizu et al., 1989), methyl brevifolin carboxylate (37)  (Iizuka et al., 
2006), geraniin (38) (Ueno et al., 1988), corilagin (39) (Shmizu et al., 1989), 
phyllanthusiin D (40) (Foo and Wong, 1992), amariin (41), amariinic acid (42), 
elaeocarpusin (43), geraniinic acid B (44), repandusinic acid (45), amarulone (46), 
furosin (47) (Foo, 1995), 1,6-digalloyl glucopyranoside (48) (Foo, 1993), catechin (49), 
epicatechin (50), gallocatechin (51), epigallocatechin (52), epicatechin 3-O-gallate (53), 
epigallocatechin 3-O-gallate (54) (Ishimaru et al., 1992).  
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         33   gallic acid   34   ellagic acid   
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              35  brevifolin carboxylic acid      COOH 
             36  ethyl brevifolin carboxylate   COOCH2CH3 
             37  methyl brevifolin carboxylate COOCH3 
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 38   geraniin      39   corilagin   
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 40  phyllanthusiin D       41   amariin 
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42   amariinic acid     43   elaeocarpusin 
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44   geraniinic acid     45   repandusinic acid 
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46   amarulone                       47   furosin 
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48  1,6-digalloyl glucopyranoside 
        R1  R2 R3 
   49 catechin   OH (β)  OH H 
   50 epicatechin   OH (α)  OH H 
   51  gallocatechin   OH (β)  OH OH 
   52 epigallocatechin  OH (α)  OH OH 
   53 epicatechin 3-O-gallate O-gallate (α) OH H 
   54 epigallocatechin 3-O-gallate  O- gallate(α) OH OH 
 
 
Flavonoids 
Flavonoids reported from P. niruri plant belongs to the flavonols and flavanone 
subclasses and their respective glycosides. The following flavonoids have been 
isolated from P. niruri: quercetin (12), rutin (13), astragalin (55), quercitrin (56), 
isoquercitrin (57) (Nara et al., 1977), kaempferol-4’-rhamnopyranoside (58), eridictyol-
7-rhamno pyranoside (59) (Chauhan et al., 1977), fisetin-4’-O-glucoside (60) (Gupta 
and Ahmed, 1984), quercetin-3-O-glucopyranoside (61) (Foo, 1993), kaempferol-3-O-
rutinoside (62) (Qian-Cutrone et al., 1996). 
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55 astragalin R1 = OH  R2 = glucose     R3 = H  
56 quercitrin R1 = OH  R2 = rhamnose R3 = OH   
57 isoquercetin R1 = OH  R2 = glucose     R3 = OH  
